TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21901454

Group type: EXPERIMENTAL
Intervention: Training on a reaction time task with anticipation of a 'Go' signal, involving a foreperiod of 1-2 seconds, performed for 480 trials/day for 12 days.
Number of subjects: 480
Study: 18054445

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing based counselling by specialized liaison service
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing based counselling by hospital physicians
Number of subjects: 595

Group type: COMPARATOR
Intervention: Hospital treatment as usual without additional counselling (Control)
Number of subjects: 595
Study: 16493125

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy (MRS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) and Magnetic Resonance Spectroscopy (MRS)
Number of subjects: 51
Study: 12759298

Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg once daily) plus anti-hyperuricaemic agents (including benzbromarone 50 mg once daily or allopurinol 200 mg twice a day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily) plus anti-hyperuricaemic agents (including benzbromarone 50 mg once daily or allopurinol 200 mg twice a day)
Number of subjects: 52
Study: 10952126

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy
Number of subjects: 0
Study: 8815570

Group type: EXPERIMENTAL
Intervention: Fragmin (2500 IU sc once daily for 90 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 29
Study: 1945215

Group type: EXPERIMENTAL
Intervention: Hydration group (2 L of water plus usual fluid)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (normal fluid intake)
Number of subjects: 2
Study: 6338842

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy with drainage (TV + D)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy with antrectomy (TV + A)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Functional assessment including ulcer recurrence
Number of subjects: 152
Study: 29947739

Group type: EXPERIMENTAL
Intervention: Conservation analysis of MSAs composed of randomly selected homologs from a PSI-BLAST search
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Combinatorial MSA sampling algorithm
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Selection of Alignment by Maximal Mutual Information (SAMMI)
Number of subjects: 1023
Study: 30481267

Group type: EXPERIMENTAL
Intervention: Seven-Gene Signature assay
Number of subjects: 202

Group type: COMPARATOR
Intervention: Surgery only patients (control group)
Number of subjects: 202
Study: 26440415

Group type: EXPERIMENTAL
Intervention: NE-SM1 NEPLUS nebulizer (test nebulizer)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pariboy SX nebulizer (control nebulizer)
Number of subjects: 20
Study: 27128831

Group type: COMPARATOR
Intervention: Bazedoxifene 20 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Bazedoxifene 40 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Bazedoxifene 80 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (5 mg and greater)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (various doses)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (1, 2.5, 5, 10, 20, 40, and 80 mg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 22427895

Group type: EXPERIMENTAL
Intervention: IV cannulation skills laboratory training (n=41)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Bedside teaching (n=40)
Number of subjects: 81
Study: 20848369

Group type: EXPERIMENTAL
Intervention: Box and Block Test (BBT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nine-Hole Peg Test (NHPT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Action Research Arm Test (ARAT)
Number of subjects: 59
Study: 17686444

Group type: EXPERIMENTAL
Intervention: Pemetrexed/platinum-based doublets (cisplatin or carboplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen (cisplatin plus etoposide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3- and 4-drug regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-platinum-based regimens
Number of subjects: 0
Study: 15655129

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 13677

Group type: COMPARATOR
Intervention: B2B2 genotype
Number of subjects: 13677
Study: 11985904

Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 1076
Study: 10681808

Group type: EXPERIMENTAL
Intervention: Lotensin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (normotensive subjects)
Number of subjects: 47
Study: 9197912

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 81

Group type: COMPARATOR
Intervention: 2'-chlordesmethyldiazepam
Number of subjects: 81
Study: 2794190

Group type: EXPERIMENTAL
Intervention: Leadup activity training program (8-hour, largely self-instructional)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (randomly selected)
Number of subjects: 26
Study: 1222752

Group type: EXPERIMENTAL
Intervention: Carbamazepine tablets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbamazepine syrup
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carbamazepine (both preparations)
Number of subjects: 20
Study: 31175806

Group type: EXPERIMENTAL
Intervention: Flaxseed lignan supplement (50 mg secoisolariciresinol diglucoside/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Flaxseed lignan supplement
Number of subjects: 42
Study: 28002198

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25381193

Group type: EXPERIMENTAL
Intervention: Baseline first phase insulin response (FPIR) ≤3 μU/mL during IvGTT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Maximal plasma glucose ≥11.1 mmol/L measured at 30, 60 and/or 90 min during OGTT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of FPIR from IvGTT and maximal plasma glucose during OGTT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-level IA-2A
Number of subjects: 50
Study: 23162100

Group type: EXPERIMENTAL
Intervention: K‐citrate (60 mEq daily)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 21719806

Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB) Plus Adhesive with rewet dentin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB) Plus Adhesive with dry dentin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: One-Step (OS) Universal Dental Adhesive System with rewet dentin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: One-Step (OS) Universal Dental Adhesive System with dry dentin
Number of subjects: 40

Group type: COMPARATOR
Intervention: One-Step (OS) Universal Dental Adhesive System
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adper Single Bond (SB) Plus Adhesive
Number of subjects: 40
Study: 19390093

Group type: EXPERIMENTAL
Intervention: Telemedicine case management
Number of subjects: 1665

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665
Study: 16882343

Group type: EXPERIMENTAL
Intervention: Home UVB treatment
Number of subjects: 196

Group type: COMPARATOR
Intervention: UVB phototherapy in a hospital outpatient clinic
Number of subjects: 196
Study: 15223788

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs) with a +2.00 addition (n = 235)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Single vision lenses (SVLs; n = 234)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs)
Number of subjects: 469
Study: 11408301

Group type: EXPERIMENTAL
Intervention: Admission cardiotocography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doppler auscultation
Number of subjects: 0
Study: 9027270

Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 126
Study: 8237086

Group type: EXPERIMENTAL
Intervention: Sitting position with solid bolus (piece of apple)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sitting position with liquid bolus (5 ml water)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Supine position with solid bolus (piece of apple)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position with liquid bolus (5 ml water)
Number of subjects: 20
Study: 3800403

Group type: EXPERIMENTAL
Intervention: MCP + DM + Lorazepam (Method B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: MCP + DM (Method A)
Number of subjects: 50
Study: 29736750

Group type: EXPERIMENTAL
Intervention: Telephone health coaching intervention
Number of subjects: 417

Group type: COMPARATOR
Intervention: Control group (HRA only)
Number of subjects: 417
Study: 27393622

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel with concurrent bevacizumab followed by AC
Number of subjects: 215

Group type: COMPARATOR
Intervention: nab-paclitaxel followed by AC
Number of subjects: 215

Group type: COMPARATOR
Intervention: AC followed by nab-paclitaxel
Number of subjects: 215

Group type: COMPARATOR
Intervention: Overall treatment arms
Number of subjects: 215
Study: 25044280

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 200/10 μg
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 μg
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Formoterol (F) 10 μg
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/S) 250/50 μg
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/S) 500/50 μg
Number of subjects: 1675
Study: 23424755

Group type: EXPERIMENTAL
Intervention: Lymphdiaral Basistropfen (verum) - 10 drops three times daily for 105 days
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo - 10 drops three times daily for 105 days
Number of subjects: 248
Study: 20196908

Group type: EXPERIMENTAL
Intervention: Family-based newsletter intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 19462557

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 172
Study: 16110851

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Propranolol + Isosorbide mononitrate (ISMN)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL) in noncirrhotic patients
Number of subjects: 137

Group type: COMPARATOR
Intervention: Propranolol + Isosorbide mononitrate (ISMN) in cirrhotic patients
Number of subjects: 137

Group type: COMPARATOR
Intervention: Drug therapy (Propranolol + ISMN)
Number of subjects: 137
Study: 12769414

Group type: EXPERIMENTAL
Intervention: Evidence-Based Medicine (EBM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic evaluations (cost-effectiveness analysis)
Number of subjects: 0
Study: 10394544

Group type: EXPERIMENTAL
Intervention: Laparoscopic culdoplasty with a CO2 laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laparoscopic culdoplasty with 5-mm laparoscopic mechanical instruments
Number of subjects: 30
Study: 8520875

Group type: EXPERIMENTAL
Intervention: Totally implanted catheters
Number of subjects: 74

Group type: COMPARATOR
Intervention: IL-2 treatment alone (41 patients)
Number of subjects: 74

Group type: COMPARATOR
Intervention: IL-2 treatment with interferon gamma (33 patients)
Number of subjects: 74
Study: 2405326

Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine/prilocaine) applied 1-75 minutes before CO2 laser treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo cream applied 1-75 minutes before CO2 laser treatment
Number of subjects: 80
Study: 649204

Group type: EXPERIMENTAL
Intervention: 200 mg thrice daily for seven days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Repetition of the seven-day course after an interval of one week
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single dose of 2400 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two 2400 mg doses on successive days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-dose groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2400 mg dosages
Number of subjects: 60
Study: 31077233

Group type: EXPERIMENTAL
Intervention: Structured group-based educational program (MEDIHEALTH)
Number of subjects: 0
Study: 28969312

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 26035677

Group type: EXPERIMENTAL
Intervention: Unilateral surgical decompression of the tibial nerve and common, superficial, and deep peroneal nerves
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (contralateral side)
Number of subjects: 42
Study: 23510357

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 500

Group type: COMPARATOR
Intervention: Men-PS
Number of subjects: 500
Study: 21617090

Group type: EXPERIMENTAL
Intervention: Nurse-coordinated care including a nephrologist
Number of subjects: 474

Group type: COMPARATOR
Intervention: Usual care coordinated by a general practitioner
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Nurse-coordinated care
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 474
Study: 18158695

Group type: EXPERIMENTAL
Intervention: MRI per os
Number of subjects: 38

Group type: COMPARATOR
Intervention: MRE
Number of subjects: 38
Study: 17130680

Group type: EXPERIMENTAL
Intervention: Omalizumab (150, 225, 300, or 375mg) administered subcutaneously every 2 or 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 100
Study: 12584276

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 150 mg/day for 4 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 31
Study: 10675831

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen-medrogestone combination
Number of subjects: 228
Study: 9116774

Group type: EXPERIMENTAL
Intervention: r-FSH with LHRH agonist
Number of subjects: 62

Group type: COMPARATOR
Intervention: r-FSH without LHRH agonist
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: r-FSH with step-up stimulation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: r-FSH with step-down stimulation
Number of subjects: 62
Study: 1439226

Group type: EXPERIMENTAL
Intervention: Breath-actuated metered dose inhaler (Aerolin in the Autohaler inhalation device)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard press and breathe metered dose inhaler
Number of subjects: 25
Study: 3104446

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31843821

Group type: EXPERIMENTAL
Intervention: Targeted, person-centred cardiorespiratory management model
Number of subjects: 1100
Study: 29302807

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH) with peritoneal closure (PC)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH) without peritoneal closure (PC)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH) with peritoneal closure (PC)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH) without peritoneal closure (PC)
Number of subjects: 192

Group type: COMPARATOR
Intervention: All groups (LAVH and VH with and without PC)
Number of subjects: 192
Study: 26699246

Group type: EXPERIMENTAL
Intervention: Five-Color Nutrition Label
Number of subjects: 11981

Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights
Number of subjects: 11981

Group type: EXPERIMENTAL
Intervention: Green Tick
Number of subjects: 11981

Group type: COMPARATOR
Intervention: Control (no front‐of‐pack exposure)
Number of subjects: 11981
Study: 25046394

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg or 0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study: 22980341

Group type: EXPERIMENTAL
Intervention: Single-session aerobic exercise with low intensity (n=14)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single-session aerobic exercise with moderate intensity (n=14)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single-session aerobic exercise with high intensity (n=13)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 51
Study: 21626816

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (50 ml)
Number of subjects: 47
Study: 16999956

Group type: EXPERIMENTAL
Intervention: FSH isoform distribution pattern assessment
Number of subjects: 0
Study: 14641117

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) (2%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonanoic acid (NAA) (40%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study: 10896228

Group type: EXPERIMENTAL
Intervention: Exercise group (3-year low intensity exercise intervention)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 140
Study: 9027792

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g i.v. preoperatively and 250 mg i.p. in the first dialysis bag (1 litre fluid)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 38
Study: 8104044

Group type: EXPERIMENTAL
Intervention: Serazepine (CGS‐15040A) at doses greater than or equal to 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 3089950

Group type: EXPERIMENTAL
Intervention: Ordinary lithium carbonate (1.5 g)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate (1.8 g)
Number of subjects: 5
Study: 30024030

Group type: EXPERIMENTAL
Intervention: Scaling with root planing in multiple sessions quadrant‐by‐quadrant (Q by Q)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Scaling with root planing within 24 hours (one stage)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Initial HbA1c < 9%
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Initial HbA1c ≥ 9%
Number of subjects: 93
Study: 27461133

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges (≥108 CFU L. reuteri ATCC PTA 5289 and ≥108 CFU L. reuteri DSM 17938, consumed 2× daily for approx. 7 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (devoid of L. reuteri)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 24893377

Group type: EXPERIMENTAL
Intervention: Orange-flavored water (OF)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lemon-flavored water (LF)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Grape-flavored water (GF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Unflavored water (W)
Number of subjects: 14
Study: 23048051

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents (R-ZES)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Both R-ZES and SES
Number of subjects: 500
Study: 21677121

Group type: EXPERIMENTAL
Intervention: Free lutein (fL) 12.2 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lutein esters (Le) 27 mg (equivalent to 13.5 mg free lutein)
Number of subjects: 72
Study: 18581587

Group type: EXPERIMENTAL
Intervention: Clotinab
Number of subjects: 124

Group type: COMPARATOR
Intervention: ReoPro
Number of subjects: 124
Study: 17307425

Group type: EXPERIMENTAL
Intervention: Unopposed estrogen (conjugated estrogen, 0.625 mg)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Estrogen + medroxyprogesterone acetate (MPA, 2.5 mg)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Combined estrogen and estrogen + MPA
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Women who took >80% of study medication
Number of subjects: 309
Study: 12943952

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily (flx20)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg daily (flx40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg plus buspirone 20 mg daily (flx20-plus-buspirone)
Number of subjects: 120
Study: 10682871

Group type: EXPERIMENTAL
Intervention: Standard Purine soy formula (180 mg purines/L from RNA)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Reduced Purine soy formula (65 mg purines/L; 26 mg/L from RNA and 39 mg/L from ribonucleotides)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Standard Purine soy formula
Number of subjects: 178

Group type: COMPARATOR
Intervention: Reduced Purine soy formula
Number of subjects: 178
Study: 9054254

Group type: EXPERIMENTAL
Intervention: Propofol plus high-dose esmolol (bolus of 1 mg/kg, then 250 micrograms.kg-1.min-1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol plus low-dose esmolol (bolus of 0.5 mg/kg, then 50 micrograms.kg-1.min-1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 60